# TARGET-HPV (NCT05108870)

> TheraT® Vectors (Vaccines) Combined With Chemotherapy to Treat HPV16 Head and Neck Cancers

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05108870
- Phase: PHASE1, PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: University of Chicago
- Conditions: Human Papilloma Virus; HPV; HPV Positive Oropharyngeal Squamous Cell Carcinoma; Head and Neck Cancer
- Interventions: HB-201; HB-202; Carboplatin; Paclitaxel; Transoral Robotic Surgery
- Enrollment: 35
- Primary outcome: Phase 1 Primary Outcome: Phase 1 Dose of HB-201 and HB-201/202 Combined with Chemotherapy
- Primary outcome: Phase 2 Primary Outcome: Deep Response Rate of Participants Treated with HB-201 or HB-201/202 Combined with Chemotherapy

## Indexed commentary on TARGET-HPV so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- YouTube: 2
- Podcasts: 2
- X threads: 2

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=target-hpv-nct05108870